The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.
Centered on CNS
Information provided by Supernus Pharmaceuticals, Inc
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS diseases. The Company has two marketed products, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). Supernus is also developing two product candidates to address large market opportunities in psychiatry, specifically within the ADHD therapeutic area.
Provides an overview of the fundamentals and limitations of presumptive and definitive drug testing, and reviews interpretation of test results.